Piperazinyl derivatives as modulators of chemokine receptor activity
    2.
    发明授权
    Piperazinyl derivatives as modulators of chemokine receptor activity 有权
    哌嗪衍生物作为趋化因子受体活性的调节剂

    公开(公告)号:US07615556B2

    公开(公告)日:2009-11-10

    申请号:US11625889

    申请日:2007-01-23

    CPC分类号: C07D295/185 C07D213/56

    摘要: The present application describes modulators of MIP-1α of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein m, T, W, R1, R4, R5, R5a and R5b are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.

    摘要翻译: 本申请描述了式(I)的MIP-1α的调节剂:其立体异构体或其药学上可接受的盐,其中m,T,W,R 1,R 4,R 5,R 5a和R 5b如本文所定义。 此外,公开了使用所述调节剂治疗和预防炎症性疾病如哮喘和过敏性疾病以及自身免疫病态如类风湿性关节炎和动脉粥样硬化的方法。

    Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
    5.
    发明授权
    Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors 有权
    用作激酶抑制剂的咪唑并吡啶和咪唑并吡嗪化合物

    公开(公告)号:US08338604B2

    公开(公告)日:2012-12-25

    申请号:US12999073

    申请日:2009-06-18

    CPC分类号: C07D401/04

    摘要: A compound of Formula (I) or Formula (II) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) or Formula (II), and methods of treating conditions associated with the activity of p38 kinase.

    摘要翻译: 式(I)或式(II)的化合物及其对映异构体,非对映异构体及其药学上可接受的盐。 还公开了含有式(I)或式(II)的化合物的药物组合物,以及治疗与p38激酶活性相关的病症的方法。

    Substituted spiro azabicyclics as modulators of chemokine receptor activity
    8.
    发明授权
    Substituted spiro azabicyclics as modulators of chemokine receptor activity 有权
    取代的螺氮氮杂双环作为趋化因子受体活性的调节剂

    公开(公告)号:US07479496B2

    公开(公告)日:2009-01-20

    申请号:US11060246

    申请日:2005-02-17

    IPC分类号: A61K31/44 C07D215/00

    摘要: The present application describes modulators of CCR3 of formula (Ia) and (Ib): or pharmaceutically acceptable salt forms thereof, wherein Z, R1, R2, R3, R4, R5, R5′, R6, a, b, c, d, and u are as defined herein in the specification. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using modulators of formula (Ia) and (Ib) are disclosed.

    摘要翻译: 本申请描述了式(Ia)和(Ib)的CCR3或其药学上可接受的盐形式的调节剂:其中Z,R1,R2,R3,R4,R5,R5',R6,a,b,c, 并且u如说明书中所定义。 此外,公开了使用式(Ia)和(Ib)的调节剂治疗和预防炎性疾病如哮喘和过敏性疾病以及类风湿性关节炎和动脉粥样硬化的自身免疫病态的方法。